Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...

Discover key insights from Soleno Therapeutics' Q2 2025 earnings call, highlighting Vykat XR's strong launch, revenue growth, EU expansion efforts & ...

TD Cowen raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $115 and keeps a Buy rating on the shares. The firm notes Soleno reported impressive Vykat XR revenue of $33M in its ...

Vykat XR may also change the levels of other medicines in the body. If you are taking any of these other medicines, your health care provider may make changes to your doses or medicines.

The Company’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 ...

About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). IMPORTANT SAFETY INFORMATION Contraindications ...

Soleno Therapeutics, Inc. Announces $200 Million Public Offering to Fund VYKAT XR Commercialization and R&D Activities July 10, 2025 — 06:11 am EDT Written by None for Quiver Quantitative -> ...

About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). IMPORTANT SAFETY INFORMATION Contraindications ...

After treatment with VYKAT XR, participants in the highly food-restricted group exhibited statistically significant (p ≤ 0.0001), clinically meaningful reductions in HQ-CT Total scores that were ...